Results 151 to 160 of about 1,177,456 (242)

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, Volume 78, Issue 11, Page 2189-2202, November 2026.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Idiopathic pulmonary fibrosis and interleukins: a bibliometric analysis [1999-2025]. [PDF]

J Thorac Dis
Xu J, Chen S, Liu L, Zhang J, Min Y, Zhou H.   +5 more
europepmc   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 4003-4016, November 2026.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Immunosenescence in Idiopathic Pulmonary Fibrosis. [PDF]

J Inflamm Res
Xiao S, Li Z, Zhang H, Cai W, Yu S, Song X.   +5 more
europepmc   +1 more source

Real‐World Progression Patterns and Potential Prognostic Factors for Trastuzumab Deruxtecan‐Related Interstitial Lung Disease in Japanese Patients With Breast or Gastric Cancer

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Interstitial lung disease (ILD)/pneumonitis is a safety concern with trastuzumab deruxtecan (T‐DXd). We characterized post‐onset changes in ILD severity and imaging patterns, and explored potential prognostic factors for fatal T‐DXd‐related ILD in Japanese patients with breast or gastric cancer.
Shinichi Sasaki, Katsunori Oikado, Tomohisa Baba, Masahiko Kusumoto, Yutaka Fujiwara, Masahiro Endo, Terufumi Kato, Yasuyuki Kurihara, Yoshinobu Saito, Kunihiro Yagihashi, Masafumi Sata, Yoshinao Sato, Hirotsugu Kenmotsu, Taiki Fukuda, Teppei Yamaguchi, Saiko Isshiki, Hiroshi Wakui, Haruki Kobayashi, Satoshi Ikeda, Motoyasu Kato, Ou Yamaguchi, Toshimi Takano, Ken Kato, Akiko Takenaka, Koji Hirata, Wataru Hashimoto, Kazuyoshi Kuwano   +26 more
wiley   +1 more source

FSP1 as the convergent hub of autophagy and ubiquitination governing ferroptosis in monocrotaline‐induced pulmonary arterial hypertension

Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Background: The crosstalk between autophagy and ferroptosis in pulmonary arterial hypertension (PAH) remains unclear. We investigated the role of FSP1 as a critical link between these processes. Methods and Findings: Mechanistically, we identified that FSP1 degradation is dually regulated by NBR1‐mediated autophagic flux and RNFT1‐dependent K63‐linked ...
Dandan Chen, Qi Jin, Lei Zhang, Wenzhi Pan, Daxin Zhou, Junbo Ge, Lihua Guan   +6 more
wiley   +1 more source

Obesity and the risk of idiopathic pulmonary fibrosis: a nationwide population-based study. [PDF]

BMJ Open Respir Res
Kim M, Lee KN, Shin DW, Han K, Lee SW.
europepmc   +1 more source

Microfluidic Profiling of an Immune Cell‐Associated Extracellular Vesicle Signature for Active Tuberculosis Diagnosis and Treatment Monitoring

Journal of Extracellular Vesicles, Volume 15, Issue 11, November 2026.
Integrating microfluidic parallel detection with an innate immune extracellular vesicle signature enables rapid active tuberculosis diagnosis from 10 µL of plasma in 30 minutes, effectively discriminating non‐tuberculous respiratory diseases and monitoring treatment response.
Eun Ju Lee, Cheng Nie, Sunyoung Park, Yun‐Jeong Kang, Minji Kang, Jake Whang, Go‐Eun Choi, Hyejon Lee, San‐Nae Cho, Kyung‐A Hyun, Sunghyun Kim, Hyo‐Il Jung, Jungho Kim   +12 more
wiley   +1 more source

Idiopathic pulmonary fibrosis with bronchogenic carcinoma

, 2009
Idiopathic pulmonary fibrosis is essentially a benign disease. We present a case of 65-year-old female patient who presented with left-sided chest pain and breathlessness.
Nair Girija, Swami Shivani, Mehta Ankur
core  

Clonal hematopoiesis is associated with progression of idiopathic pulmonary fibrosis. [PDF]

JCI Insight
Asarian L, Jia J, Sirokha D, Paulini L, Dietel D, Stoleriu MG, Frankenberger M, Yildirim AÖ, Götze KS, Behr J, Hunninghake GM, Fernandez IE.   +11 more
europepmc   +1 more source